Streetbeat News

Analyst Ratings

FIVE

Citigroup analyst Paul Lejuez maintains a Buy rating on Five Below (NASDAQ:FIVE) and lowers the price target from $225 to $220.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 10:32 am

SSTK

Needham analyst Bernie McTernan reiterated a Buy rating on Shutterstock (NYSE:SSTK) and maintained a $90 price target.

Portfolio Pulse from richadhand@benzinga.com

May 24, 2023 | 10:32 am

VFC

Citigroup analyst Paul Lejuez maintains a Neutral rating on VF Corporation (NYSE:VFC) and lowers the price target from $22 to $20.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 10:31 am

TRNS

HC Wainwright & Co. analyst Scott Buck maintains a Buy rating on Transcat (NASDAQ:TRNS) and raises the price target from $96 to $102.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 10:31 am

ELYS

HC Wainwright & Co. analyst Scott Buck reiterates a Buy rating on Elys Game Technology (NASDAQ:ELYS) and maintains a $2 price target.

Portfolio Pulse from richadhand@benzinga.com

May 24, 2023 | 10:31 am

INTU

Citigroup analyst Steven Enders maintains a Buy rating on Intuit (NASDAQ:INTU) and raises the price target from $475 to $495.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 10:30 am

WSM

Barclays analyst Adrienne Yih maintains an Equal-Weight rating on Williams-Sonoma (NYSE:WSM) and lowers the price target from $135 to $126.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 10:29 am

AAPL

Jim Cramer advises investors to focus on companies with customer service as their core philosophy, highlighting Apple Inc (NASDAQ:AAPL) as a prime example. He believes Apple's customer-first mentality and ability to create innovative products make it a strong investment choice.

Portfolio Pulse from Bhavik Nair

May 24, 2023 | 10:29 am

SEDG

Barclays analyst Christine Cho maintains an Overweight rating on SolarEdge Technologies (NASDAQ:SEDG) and lowers the price target from $392 to $390.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 10:28 am

PTCT

Barclays analyst Gena Wang maintains an Equal-Weight rating on PTC Therapeutics (NASDAQ:PTCT) and lowers the price target from $57 to $48.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 10:28 am